New Clinical Trial Findings Optimize Antibiotic Treatment for Staphylococcal Infections

The SNAP Trial has revealed that cefazolin is as effective as cloxacillin for methicillin-susceptible Staphylococcus aureus (MSSA) infections, with fewer adverse effects. For penicillin-susceptible Staphylococcus aureus (PSSA), benzylpenicillin proved equally effective and safer than cloxacillin, reducing kidney damage and mortality. These significant findings, published in leading medical journals, are expected to revise current treatment protocols for these common bloodstream infections.